| Autor: |
Cordery R J, Hall M, Cipolotti L, Al-Sarraj S, O'Donovan D G, Davidson L, Adlard P, Rossor M N, Cordery, R J, Hall, M, Cipolotti, L, Al-Sarraj, S, O'Donovan, D G, Davidson, L, Adlard, P, Rossor, M N |
| Předmět: |
|
| Zdroj: |
Journal of Neurology, Neurosurgery & Psychiatry; Oct2003, Vol. 74 Issue 10, p1412-1416, 5p, 3 Charts |
| Abstrakt: |
Background: Most cases of Creutzfeldt-Jakob disease (CJD) in recipients of human cadaveric growth hormone present with a cerebellar syndrome. Dementia is thought to occur late and as a minor feature of the illness. However, neuropsychology data published on these cases are largely qualitative and anecdotal. The first published case does include a neuropsychological assessment seven months after the onset of a cerebellar syndrome, showing evidence of intellectual decline. Subsequent reports hint that cognitive problems may be present in the initial stages of the illness.Objective: To assess early cognition in Creutzfeldt-Jakob disease in recipients of pituitary derived human growth hormone.Methods: Detailed neuropsychology assessment is reported at referral (mean 4.5 months from the onset of symptoms; range 4 to 6 months) in five patients with histologically proven human growth hormone derived CJD.Results: All cases presented with a cerebellar syndrome and only one had noticed mild memory problems. On formal testing, however, four had demonstrable mild intellectual decline, as measured on the WAIS-R. One case showed selective visual memory impairment and frontal executive dysfunction.Conclusions: These findings suggest that, although not the presenting feature, mild cognitive decline may be evident in the early stages of CJD associated with human cadaveric growth hormone treatment. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
